State of Wisconsin Investment Board bought a new position in Global Blood Therapeutics, Inc. (NASDAQ:GBT) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 28,000 shares of the company’s stock, valued at approximately $766,000. State of Wisconsin Investment Board owned approximately 0.06% of Global Blood Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Legal & General Group Plc increased its holdings in Global Blood Therapeutics by 10.1% in the 1st quarter. Legal & General Group Plc now owns 4,816 shares of the company’s stock worth $178,000 after acquiring an additional 440 shares in the last quarter. American International Group Inc. increased its holdings in Global Blood Therapeutics by 24.1% in the 1st quarter. American International Group Inc. now owns 10,031 shares of the company’s stock worth $370,000 after acquiring an additional 1,945 shares in the last quarter. Asset Management One Co. Ltd. purchased a new stake in Global Blood Therapeutics in the 1st quarter worth approximately $130,000. Great West Life Assurance Co. Can purchased a new stake in Global Blood Therapeutics in the 1st quarter worth approximately $129,000. Finally, Bank of America Corp DE increased its holdings in Global Blood Therapeutics by 103.6% in the 1st quarter. Bank of America Corp DE now owns 7,141 shares of the company’s stock worth $263,000 after acquiring an additional 3,633 shares in the last quarter. 86.07% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “State of Wisconsin Investment Board Buys Shares of 28,000 Global Blood Therapeutics, Inc. (GBT)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/10/state-of-wisconsin-investment-board-buys-shares-of-28000-global-blood-therapeutics-inc-gbt.html.

Several equities research analysts recently issued reports on the stock. BidaskClub raised shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. Cowen and Company reissued an “outperform” rating and issued a $83.00 target price on shares of Global Blood Therapeutics in a report on Monday, August 14th. J P Morgan Chase & Co reissued an “overweight” rating and issued a $46.00 target price (up from $44.00) on shares of Global Blood Therapeutics in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. assumed coverage on shares of Global Blood Therapeutics in a report on Friday, August 4th. They issued an “outperform” rating and a $53.00 target price for the company. Finally, Morgan Stanley reissued an “overweight” rating on shares of Global Blood Therapeutics in a report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the stock. Global Blood Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $49.73.

Global Blood Therapeutics, Inc. (GBT) opened at 27.60 on Friday. Global Blood Therapeutics, Inc. has a 1-year low of $13.35 and a 1-year high of $41.15. The company’s market capitalization is $1.21 billion. The firm has a 50-day moving average price of $28.02 and a 200 day moving average price of $30.03.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings data on Monday, August 7th. The company reported ($0.55) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.61) by $0.06. During the same period in the previous year, the firm earned ($0.58) earnings per share. On average, equities analysts predict that Global Blood Therapeutics, Inc. will post ($2.45) EPS for the current year.

In other news, insider Jung Choi sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $30.00, for a total value of $90,000.00. Following the completion of the sale, the insider now directly owns 141,655 shares in the company, valued at $4,249,650. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Deval L. Patrick sold 27,053 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $29.69, for a total value of $803,203.57. Following the completion of the sale, the director now owns 12,053 shares of the company’s stock, valued at $357,853.57. The disclosure for this sale can be found here. Insiders sold 33,053 shares of company stock valued at $983,204 over the last 90 days. Company insiders own 5.30% of the company’s stock.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics, Inc. (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Stock Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related stocks with our FREE daily email newsletter.